Alan Hoberman
Director/Miembro de la Junta en BIOXYTRAN, INC. .
Fortuna: 118 102 $ al 31/05/2024
Perfil
Alan M.
Hoberman is currently the President & Chief Executive Officer at Argus International, Inc. and an Independent Director at BioXyTran, Inc. He previously worked as the Executive Director-Site Operations & Toxicology at Argus Research Laboratories, Inc. from 1991 to 2013, and as an Independent Director at Boston Therapeutics, Inc. from 2014 to 2017.
He also served as an Independent Director and Director at Oxygen Therapy, Inc. and BioXyTran, Inc., respectively.
Hoberman received his undergraduate degree from Drexel University, his graduate degree from The University of Arkansas, and his doctorate from Pacific Western University.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
BIOXYTRAN, INC.
0.58% | 19/04/2024 | 1 009 422 ( 0.58% ) | 118 102 $ | 31/05/2024 |
Cargos activos de Alan Hoberman
| Empresas | Cargo | Inicio |
|---|---|---|
| BIOXYTRAN, INC. | Director/Miembro de la Junta | 02/11/2018 |
Argus International, Inc.
 Argus International, Inc. Industrial MachineryProducer Manufacturing Argus International, Inc. designs and manufactures machinery for the processing of printed circuit boards. Its products include LPI Spray Coating, Thin Film Coating, Hot Air Leveling, and Fusing. The company was founded on March 1, 1965 and is headquartered in Ringoes, NJ. | Director Ejecutivo | - |
Antiguos cargos conocidos de Alan Hoberman.
| Empresas | Cargo | Fin |
|---|---|---|
Oxygen Therapy, Inc.
 Oxygen Therapy, Inc. Pharmaceuticals: MajorHealth Technology Oxygen Therapy, Inc. is an early stage pharmaceutical company, which engages in the development, manufacture, and commercialization of an innovative platform of oxygen therapeutic treatments for hypoxic conditions and necrosis prevention. Its product pipeline includes OTI-629, an anti-necrosis drug; and OTI-1011, a resuscitative agent for wound healing applications. The company was founded by David Platt on May 20, 2016 and is headquartered Newton, MA. | Director/Miembro de la Junta | 03/08/2018 |
| NANOMIX CORPORATION | Director/Miembro de la Junta | 15/09/2017 |
| Argus Research Laboratories, Inc. | Corporate Officer/Principal | 01/01/2013 |
BioXyTran, Inc. /Old/
 BioXyTran, Inc. /Old/ Pharmaceuticals: MajorHealth Technology BioXyTran, Inc. operates as a biopharmaceutical company. The firm focuses on the development and commercialization of treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. The company was founded in 2017 and is headquartered in Newton, MA. | Director/Miembro de la Junta | - |
Formación de Alan Hoberman.
| Pacific Western University | Doctorate Degree |
| The University of Arkansas | Graduate Degree |
| Drexel University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 6 |
|---|---|
Boston Therapeutics, Inc.
 Boston Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Boston Therapeutics, Inc. is a pharmaceutical company, which engages in the development, manufacture, and commercialization of novel compounds based on complex carbohydrate chemistry. Its products are designed to help manage blood sugar, treat pre-diabetes, and diabetes related pathologies. Its drug candidates comprises of BTI320, BTI-410, and IPOXYN. The company was founded by David Platt and Kenneth A. Tassey Jr. on August 24, 2009 and is headquartered in Lawrence, MA. | Health Technology |
Argus International, Inc.
Argus International, Inc. Industrial MachineryProducer Manufacturing Argus International, Inc. designs and manufactures machinery for the processing of printed circuit boards. Its products include LPI Spray Coating, Thin Film Coating, Hot Air Leveling, and Fusing. The company was founded on March 1, 1965 and is headquartered in Ringoes, NJ. | Producer Manufacturing |
Oxygen Therapy, Inc.
Oxygen Therapy, Inc. Pharmaceuticals: MajorHealth Technology Oxygen Therapy, Inc. is an early stage pharmaceutical company, which engages in the development, manufacture, and commercialization of an innovative platform of oxygen therapeutic treatments for hypoxic conditions and necrosis prevention. Its product pipeline includes OTI-629, an anti-necrosis drug; and OTI-1011, a resuscitative agent for wound healing applications. The company was founded by David Platt on May 20, 2016 and is headquartered Newton, MA. | Health Technology |
BioXyTran, Inc. /Old/
BioXyTran, Inc. /Old/ Pharmaceuticals: MajorHealth Technology BioXyTran, Inc. operates as a biopharmaceutical company. The firm focuses on the development and commercialization of treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. The company was founded in 2017 and is headquartered in Newton, MA. | Health Technology |
| BioXyTran, Inc. | |
| Argus Research Laboratories, Inc. |
- Bolsa de valores
- Insiders
- Alan Hoberman
